Folks-At-Risk for Interstitial Lung Disease (FAR-ILD) (COVID-19)
Sponsor: |
National Institutes of Health |
Enrolling: |
Male and Female Patients |
IRB Number: |
AAAR1916C |
Contact: |
M. Atif Choudhury: 646-641-3521 / mac2463@columbia.edu |
Have you recovered from COVID-19 pneumonia? The FAR-ILD study is designed to detect and study the earliest stages of ILD in at-risk adults, including those who have had a severe viral pneumonia. FAR-ILD is a non-interventional study. This means that FAR-ILD is not involved in testing any new interventions or therapies. The purpose of FAR-ILD is to gather data on adults at risk for developing ILD over a long period of time in order to help physicians and investigators better understand interstitial lung disease. There is no cost associated with participating in FAR-ILD and your insurance will not be billed. All study procedures are paid for in full by the National Institute of Health. If you enroll in the FAR-ILD study, you may be asked to undergo the following study-related procedures: CAT scan, Pulmonary Function Testing, blood draw from a vein, bronchoscopy, & return visits.
This study is closed
Investigator
Christine Kim Garcia, MD
Have you ever been hospitalized at NewYork-Presbyterian due to COVID-19? |
Yes |
No |
Are you over the age of 21? |
Yes |
No |